Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Sanjit Kumar

DiaScan Inc., Atlanta

Title: Leveraging deep learning and feature extraction to analyze and classify lung tumors and nodules from a chest computed tomography scan

Biography

Biography: Sanjit Kumar

Abstract

Among all types of cancers, lung cancer ranks highest on mortality rate. The only way to diagnose malignant lung cancer is by performing a biopsy or seeing the growth of a malignant tumor between scans, both of which usually lead to late diagnosis and metastasis. This decreases chances of survival dramatically. To make matters worse, current softwares that radiologists use do not really help with analysis, diagnosis, and prognosis. Most CAD softwares do not even automatically calculate pertinent tumor features. Because of this, the false positive rate hovers around 90% nationally, with one NIH study having a false positive rate of 96.4%. DiaScan uses deep learning and feature extraction on CT scans and medical data in order to accurately characterize lung cancer. DiaScan strives to detect cancer at an early stage, reduce the high false positive rate, decrease the amount of unneeded biopsies and repeat scans, assist radiologists by offering better tools and features, and minimize overall costs. DiaScan recieved over 10,000 patients from the National Cancer Institute in order to pursue their research, and is in the middle of developing this software to replace current methods of analyzation. DiaScan’s software will be able to intelligently extract tumor characteristics (size, density, calcifications, spiculations, etc.), predict factors of prognosis (type, stage, grade, etc.), and put all this information into a huge deep neural network in order to classify the tumor as benign or malignant, without invasive procedures. Overall, DiaScan’s research has the potential to help millions of lives around the world.